Antimetastatic Activity of the Novel Spin-Labeled Nitrosourea Derivative SLNU on Spontaneous Lung Metastases of the Lewis Lung Carcinoma

ABSTRACT

The antimetastatic activity of newly synthetized original spin-labeled nitrosourea derivative SLNU in comparison with clinically used nitrosourea antitumor drug lomustin on spontaneous lung metastases of Lewis lung carcinoma (LLC) in BDF1 hybrid mice has been studied. The established effects were “dose-dependent” and “schedule-dependent” and correlated well with the optimal clinical schedule of administration of nitrosoureas. At the used experimental design with intermittent administration both drugs inhibited significantly the growth of LLC metastases (maximal TMI% for SLNU was 100%, and for CCNU—85.8%), but with insignificant effect on the growth of the primary tumor. The newly synthetized original nitrosourea SLNU showed some advantages in its antimetastatic potential in comparison with the clinically used drug lomustin. Further complex studies in this field are in progress.